Skip to main content

Table 1 Log odds ratios (95% CIs) for the treatment effect β and the regression coefficients γ calculated using BPSA and PSA.

From: Covariate balance in a Bayesian propensity score analysis of beta blocker therapy in heart failure patients

Description

Parameter

Log Odds Ratio (95% Interval Estimate)

  

BPSA

PSA

Beta blocker

β

-0.21 (-0.37, -0.05)

-0.31 (-0.46, -0.15)

Demographics

   

   Female Sex

γ 1

0.17 (0.06, 0.29)

0.12 (-0.01, 0.25)

   Age

   

< 65 (reference)

.

0.00

0.00

65 - 74

γ 2

-0.19 (-0.32, -0.04)

-0.09 (-0.3, 0.12)

75 - 84

γ 3

-0.40 (-0.56, -0.24)

-0.21 (-0.41, 0.00)

> 85

γ 4

-0.71 (-0.94, -0.46)

-0.37 (-0.59, -0.14)

Comorbid conditions

   

   Cerebrovascular dis.

γ 5

-0.11 (-0.67, 0.44)

0.25 (-0.46, 0.96)

   COPD

γ 6

-0.32 (-0.60, -0.06)

-0.89 (-1.30, -0.49)

   Hyponatremia

γ 7

-0.02 (-0.26, 0.21)

0.03 (-0.33, 0.39)

   Metastatic disorder

γ 8

-1.42 (-2.33, -0.56)

-0.40 (-1.37, 0.57)

   Renal disease

γ 9

-0.17 (-0.32, 0.01)

0.38 (0.15, 0.62)

   Ventricular arrhythmia

γ 10

-0.12 (-0.63, 0.44)

0.12 (-0.62, 0.86)

   Liver disease

γ 11

-0.52 (-1.03, -0.08)

-1.11 (-2.04, -0.19)

   Malignancy

γ 12

-0.78 (-1.19, -0.34)

-0.06 (-0.57, 0.45)

   Shock

γ 13

-0.06 (-0.56, 0.39)

-0.12 (-0.83, 0.58)

Hospitalization

   

   Transferred

γ 14

-0.41 (-0.58, -0.25)

-0.01 (-0.22, 0.20)

   Stay (10 day intvs.)

γ 15

-0.13 (-0.18, -0.09)

-0.05 (-0.11, 0.01)

Heart failure medications

   

   Digoxin

γ 16

-0.02 (-0.11, 0.07)

0.00 (-0.14, 0.13)

   Diuretic

γ 17

0.28 (0.09, 0.48)

0.72 (0.54, 0.90)

   CCB

γ 18

0.22 (0.08, 0.35)

0.27 (0.10, 0.44)

   ACE inhibitor

γ 19

0.29 (0.11, 0.45)

0.61 (0.47, 0.76)

   ARB

γ 20

0.18 (-0.06, 0.46)

0.53 (0.19, 0.87)

   Statin

γ 21

0.91 (0.65, 1.24)

0.94 (0.76, 1.12)